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ABSTRACT 
Src homology 3 (SH3) domains bind 
proline-rich linear motifs in eukaryotes. By 
mediating inter- and intramolecular interactions, 
they regulate the functions of many proteins 
involved in a wide variety of signal transduction 
pathways. Phosphorylation at different tyrosine 
residues in SH3 domains have been reported 
previously. In several cases, the functional 
consequences have also been investigated. 
However, a full understanding of the effects of 
tyrosine phosphorylation on the ligand interactions 
and cellular functions of SH3 domains requires 
detailed structural, atomic-resolution studies along 
with biochemical and biophysical analyses. Here, 
we present the first crystal structures of 
tyrosine-phosphorylated human SH3 domains 
derived from the Abelson-family kinases ABL1 
and ABL2 at 1.6 and 1.4 Å resolutions, 
respectively. The structures revealed that 
simultaneous phosphorylation of Tyr-89 and 
Tyr-134 in ABL1, or the homologous residues 
Tyr-116 and Tyr-161 in ABL2 induce only minor 
structural perturbations. Instead, the phosphate 
groups sterically blocked the ligand-binding 
grooves, thereby strongly inhibiting the interaction 
with proline-rich peptide ligands. Although some 
crystal contact surfaces involving 
phosphotyrosines suggested the possibility of 
tyrosine-phosphorylation induced dimerization, we 
excluded this possibility by using small-angle 
X-ray scattering (SAXS), dynamic light scattering 
(DLS), and NMR relaxation analyses. Extensive 
analysis of relevant databases and literature 
revealed that the residues phosphorylated in our 
model systems are not only well conserved in 
other human SH3 domains, but that the 
corresponding tyrosines are known 
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phosphorylation sites in vivo in many cases. We 
conclude that tyrosine phosphorylation might be a 
mechanism involved in the regulation of the 
human SH3 interactome. 
 ________________________________________ 
 
Src homology 3 (SH3) domains are 
protein-protein interaction domains in eukaryotes 
involved in various intracellular signaling 
pathways (1,2). More than 200 human proteins are 
known to possess one or more SH3 domains. 
These proteins play various roles in fundamental 
cellular processes, such as the regulation of 
cellular movement or proliferation, and are also 
involved in the development of cancer and several 
other disorders. SH3 domains are relatively small 
(~60 residues) and have an antiparallel β-sandwich 
topology that is formed by five β-strands (βa, βb, 
βc, βd, and βe) connected by three loops (RT, 
N-Src, and distal loops) and a short 310 helix 
(Fig. 1/A) (1,2). SH3 domains usually bind short, 
proline-rich sequences within intrinsically 
unstructured regions of partner proteins. These 
linear motifs adopt a left-handed polyproline 
type II helix conformation. Some SH3 domains are 
also involved in intramolecular interactions. The 
most strictly defined consensus sequence of the 
SH3-binding linear motifs is PxxP, where “x” 
denotes any amino acid. There is usually a 
positively charged residue on either side of the 
consensus motif (+xxPxxP or xPxxPx+) (1,2). The 
shallow, hydrophobic ligand-binding groove 
bounded by the RT and the N-Src loops is mostly 
comprised of aromatic residues. This interface can 
be further divided into three smaller pockets 
(Pocket I-III). Pocket I and II are mainly 
hydrophobic and accommodate two residues of the 
binding motif (“Px” or “xP”, where “x” is a 
hydrophobic residue). One or more negatively 
charged residue of the RT loop can often be found 
in Pocket III orienting the ligands through 
electrostatic interaction with a positively charged 
residue on either side of the PxxP motif (Fig. 1/A) 
(3). 
A recent study showed that tyrosine 
phosphorylation occurs frequently in SH3 domains 
(4). Most of the involved tyrosines are part of the 
ligand binding groove, and the result of this 
post-translational modification was the inhibition 
of partner binding in vivo in the majority of 
reported cases (4). However, to fully understand 
the role and function of tyrosine phosphorylation, 
detailed structural studies at atomic resolution 
complemented by biochemical and biophysical 
methods assessing SH3-ligand interactions would 
be crucial. Therefore, we have chosen ABL1 and 
ABL2, two SH3-containing non-receptor tyrosine 
kinases belonging to the ABL family (5), as a 
model system to study SH3 domain tyrosine 
phosphorylation in vitro. 
ABL kinases are key regulators of 
different signal transduction pathways in 
numerous cell types influencing proliferation, 
differentiation, survival, death, morphology, 
motility, and adhesions of cells (5). The SH3 
domains of ABL1 and ABL2 or their 
constitutively active chimeric fusion protein forms 
(which are responsible for certain human 
leukemias, such as BCR-ABL (6)) were reported 
to be phosphorylated in vivo at three homologous 
tyrosine residues: Tyr89 (7,8) and Tyr134 (8,9) 
within and Tyr112 outside of the ligand binding 
groove in ABL1, while Tyr116 and Tyr161 (10) 
within and Tyr139 (10) outside of the ligand 
binding groove in ABL2 (Fig. 1/B). While 
tyrosine phosphorylation at multiple sites within 
the SH3-SH2 region was found to be necessary for 
full BCR-ABL transforming activity, substitution 
of Tyr89 to phenylalanine was solely sufficient to 
strongly reduce BCR-ABL-mediated 
transformation (8). Inhibition of myeloid Src 
family kinases, which are thought to be the 
enzymes phosphorylating this region in vivo (7,8), 
induced growth arrest and apoptosis in 
BCR-ABL-transformed cells (11). 
In the present study, we performed a 
database analysis to identify phosphorylated SH3 
domains in the human proteome. Four major 
tyrosine phosphorylation sites were found; all 
affecting conserved tyrosine residues in positions 
N, M1, M2, and C of the ligand binding groove 
(see Fig. 1/A). The SH3 domains of ABL1 and 
ABL2 kinases were used to investigate the 
functional and structural effects of tyrosine 
phosphorylation of the two most prominent sites, 
N (Tyr89 in ABL1 and Tyr 116 in ABL2) and C 
(Tyr134 in ABL1 and Tyr 161 in ABL2), using 
classical biochemical binding assays, 1H-15N NMR 
spectroscopy, CD spectroscopy, DLS, SAXS and 
X-ray crystallography. To the best of our 
knowledge, these are the first phosphorylated SH3 
domain structures published so far. Comparison of 
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phosphorylated, non-phosphorylated and 
ligand-bound ABL SH3 structures revealed no 
large-scale structural rearrangements, however, 
ligand binding was strongly inhibited by either of 
the introduced phosphate groups. These were 
sterically blocking the binding groove making it 
physically inaccessible for the ligands. 
Phosphorylation of homologous tyrosine residues 
in other SH3 domains might block ligand binding 
through a similar molecular level mechanism in 
general. 
 
Results 
Identification of conserved tyrosine 
phosphorylation sites within human SH3 
domains 
To assess the importance of tyrosine 
phosphorylation among SH3 domains and identify 
novel potential regulatory sites, all human SH3 
sequences were aligned (Table S1) and 
subsequently filtered by the occurrence of tyrosine 
phosphorylation (using the PhosphoSitePlus 
database; Table S2). We found 168 individual 
tyrosine phosphorylation sites in 94 different 
human SH3 domains. Phosphorylation sites were 
mapped onto the aligned sequences (Table S2). 
The four most prominent sites are highlighted on 
the sequence logo representation of the alignment 
(Fig. 2). Note that all of these modifications affect 
positions N (10), M1 (12), M2 (50), and C (55) of 
the ligand binding groove (see Fig. 1/A). The 
unfiltered multiple alignment demonstrates that 
tyrosine residues in these positions are well 
conserved (Table S1). The specific occurrence of 
Tyr at positions N, M1, M2, and C among human 
SH3 domains is 43.2%, 52.0%, 15.0%, and 53.5%, 
respectively. 
The two most common tyrosine 
phosphorylation sites are positions N and C with 
32 and 35 occurrences in the database, 
respectively. These residues are located in close 
proximity to each other in the binding grooves of 
SH3 domains (see Fig. 1/A) and their aromatic 
rings form the hydrophobic “Pocket I”. We found 
two other major phosphorylation sites at positions 
M1 and M2 with 13 and 20 occurrences, 
respectively. These residues are also important in 
the formation of the ligand binding groove. The 
overlap of major phosphorylation sites with key 
structural elements of the binding groove strongly 
suggests that phosphorylation of either one or 
more tyrosine(s) at position(s) N, M1, M2, and C, 
hereinafter referred to as “TyrN”, “TyrM1”, 
“TyrM2”, and “TyrC”, respectively, might inhibit 
ligand binding. 
 
In vitro phosphorylation of the SH3 domain of 
ABL1 and ABL2 
First, we were screening for tyrosine 
kinases that can be expressed in an active form in 
E. coli and can be used to catalyze the selective 
phosphorylation of our SH3 domains. Briefly, 
kinase domains from distant tyrosine-kinase 
families (SRC, ABL, Ephrin, Tec) were tested 
both as His-tagged and GST-tagged proteins. We 
observed acceptable expression levels of 
autophosphorylated, active His-EphB1, His-HCK, 
and GST-ABL1 (data not shown). Both 
ABL1 SH3 and ABL2 SH3 were selectively and 
effectively phosphorylated by His-EphB1 at TyrN 
and TyrC (Fig. 1/B) as it was shown by the 
combination of anion exchange chromatography 
and mass spectrometry (Fig. S1). Even after 
extensive incubation in the presence of excess 
ATP, tyrosine residues outside of the binding 
groove (Tyr139 in ABL2 or Tyr112 in ABL1) 
were not phosphorylated at detectable levels in our 
experiments. Kinase Reactions were scaled up to 
obtain doubly-phosphorylated ABL1 SH3 and 
ABL2 SH3 (referred to as ABL1 SH3pYn/pYc and 
ABL2 SH3pYn/pYc throughout this work, 
respectively) on a milligram scale (see Materials 
and Methods). As we could not achieve acceptable 
separation of the monophosphorylated SH3 
domains (Fig. S1), the following 
tyrosine-to-phenylalanine mutants were generated: 
ABL1 SH3Tyr89Phe, ABL1 SH3Tyr134Phe, 
ABL2 SH3Tyr116Phe, and ABL2 SH3Tyr161Phe, 
referred to as ABL1 SH3YnF, ABL1 SH3YcF, 
ABL2 SH3YnF, and ABL2 SH3YcF, respectively 
(Fig. 1/C). With this approach, the effects of the 
two individual phosphorylation events could be 
investigated separately. Importantly, each 
phosphorylated Tyr-to-Phe mutant was eluted as a 
single peak from our anion exchange column (data 
not shown) corresponding to a singly-
phosphorylated protein as shown by mass 
spectrometry. The lack of chromatographic peaks 
corresponding to doubly-phosphorylated variants 
showed that EphB1 is indeed specific for binding 
groove tyrosines. 
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Tyrosine-phosphorylation strongly interferes 
with binding of ABL1 SH3 and ABL2 SH3 to 
peptide ligands derived from 3BP-2 and ABI2 
The intrinsic tryptophan fluorescence 
intensity signal was used to determine binding 
affinities of in vitro phosphorylated and 
non-phosphorylated ABL1 and ABL2 SH3 
domains for peptide ligands corresponding to 
proline-rich motifs of 3BP-2 and ABI2 
(HPPAYPPPPVPT and TPPTQKPPSPPMS, 
respectively), known binding partners of ABL1 
(12,13). A remarkable blue shift was observed in 
the spectra of both ABL1 SH3 and ABL2 SH3 
upon addition of the ligands (Fig. 3/A). As the 
highest difference in the fluorescence intensity 
between the ligand-bound and free SH3 domains 
was observed at 318 nm, we followed all titrations 
at this wavelength. Phosphorylation of wild-type 
ABL1 and ABL2 SH3 domains at both tyrosines 
resulted in total loss of ligand binding (Fig. 3/B 
and 3/C). Dissociation constants obtained for 
Tyr-to-Phe mutants (3BP-2: ~4 to 11 μM, ABI2: 
~100 to 200 μM) were generally close to those 
obtained for wild-type proteins (3BP-2: ~ 2 μM, 
ABI2: ~100 to 150 μM) showing that the 
introduced mutations had only minor effects on 
ligand binding (Table 1). ABL1 SH3YnF/pYc and 
ABL2 SH3YnF/pYc showed no interaction with 
either of the ligands. A strong inhibition of ligand 
binding was also observed in the case of 
ABL1 SH3pYn/YcF and ABL2 SH3pYn/YcF, however, 
some “residual” binding could be detected (3BP-2: 
Kd > 100 μM, ABI2: very weak). 
 
Crystal structures of tyrosine-phosphorylated 
ABL1 and ABL2 SH3 domains reveal atomic 
level details of the inhibition of ligand binding 
To obtain atomic-level insights into the 
mechanism of inhibition and to understand the 
somewhat different impact of the two 
phosphorylation events on ligand binding, we 
crystallized the doubly-phosphorylated SH3 
domains ABL1 SH3pYn/pYc and ABL2 SH3pYn/pYc 
and the non-phosphorylated ABL2 SH3 as no 
atomic resolution structure of this domain had 
been reported previously. Crystal structures were 
solved at 1.6 Å, 1.4 Å, and 2.0 Å resolutions, 
respectively (Fig. 4). Crystallographic statistics are 
reported in Table S3. 
The sequences of the SH3 domains of 
ABL1 and ABL2 are highly similar. There are 
only four different residues in the 𝛽𝑐 strand and 
one in the N-Src loop: Cys119, Ala121, Gln122, 
Thr123, and His114 in ABL1 correspond to 
Ser146, Val148, Arg149, Ser150, and Gln141 in 
ABL2, respectively (see Fig. 1/B). By comparing 
the ABL1 and ABL2 SH3 domain structures 
(Fig. S2), it seems unlikely that these differences 
could significantly influence the structure or 
function of the ligand binding groove. The most 
significant differences based on Cα-Cα distances 
can be found in the RT- ("SGD" region) and distal 
loops ("TKNG" and "SKNG" regions in ABL1 
and ABL2, respectively) (Fig. S2), however, it 
seems very likely that different crystal contacts are 
the determining factor here. 
With the comparison of the 
phosphorylated SH3 domains to their 
non-phosphorylated counterparts, no large-scale 
structural rearrangements could be observed 
(Fig. 4). We could only see slight differences in 
certain regions (e.g. “VASGDN” region in the 
RT-loop and “KN” region in the distal loop, 
Fig. S2), however, these again seem to be more 
related to differences in crystal contacts rather 
than being the result of tyrosine phosphorylation. 
Moreover, there are no differences in sidechain 
conformations that could be obviously interpreted 
as the result of tyrosine phosphorylation. 
To understand the regulatory effect of 
phosphorylation on ligand binding, we aligned the 
phosphorylated SH3 structures to a ligand-bound 
ABL1 SH3 structure (PDB: 1ABO (14), 
Fig. 5/A). This comparison clearly showed that the 
phosphate group of pTyrC occupies the center of 
the binding groove changing the hydrophobic 
character of two neighboring pockets (Pocket I 
and II) to hydrophilic, thus making it impossible 
for the protein to accommodate the ligand in the 
right position (Fig. 5/B). As ligand binding would 
result in serious steric clashes between the peptide 
backbone and the phosphate group, it is not 
surprising that this modification has a very strong 
inhibitory effect (see Fig. 3/B and 3/C). The 
phosphate group of pTyrN is located at the edge of 
the binding groove (Fig. 5/A). Although it is 
pointing outwards, it still occupies some space that 
would be necessary for the peptide backbone to 
bind (in Pocket I). The somewhat weaker 
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inhibition in this case (Fig. 3/B and 3/C) might be 
explained by the higher flexibility of this sidechain 
(see the different conformations in the two 
crystallographic monomers) and the greater 
distance of the phosphate oxygens from the 
peptide backbone (Fig. 5/C). Moreover, the 
presence of this phosphate group affects mainly 
the C-terminal end of the peptide, potentially 
allowing some “residual” interaction with other 
parts of the binding groove. 
 
Tyrosine-phosphorylation does not significantly 
affect the structure of ABL1 SH3 and ABL2 SH3 
in solution 
To show that the introduced phosphate 
groups or Tyr-to-Phe mutations did not induce 
significant structural changes in solution, we 
acquired far-UV CD spectra of all SH3 derivatives 
(Fig. S3) and determined the secondary structure 
contents by BeStSel (http://bestsel.elte.hu/) 
(Table S4). All studied SH3 variants were nearly 
exclusively comprised of relaxed and right-twisted 
antiparallel beta-sheets (~10 and ~18 residues, 
respectively), turns (~5 residues) and other 
structures (~27 residues), while no helices, parallel 
or left-twisted antiparallel beta-sheets were 
observed. The fact that only slight differences 
were detected in the secondary structure contents 
strongly suggests that the three-dimensional 
structure of ABL1 SH3 and ABL2 SH3 is neither 
significantly affected by the mutations, nor by 
phosphorylation. 
Similarly, 1H-15N HSQC spectra of 
non-phosphorylated and phosphorylated 
ABL1 SH3 derivatives (Fig. S4) indicate only 
minor structural perturbations upon tyrosine 
phosphorylation (Fig. S5) showing that the overall 
structural integrity of the protein was not affected 
by these molecular level alterations. The behavior 
of the N- and C-terminal regions (Phe85-Thr102 
and Ser132-Val138, respectively) seem to be 
correlated as phosphorylation of either TyrN or 
TyrC mutually affects the environment of the 
other. This is manifested in a similar overall 
pattern of phosphorylation-induced chemical shift 
changes over the SH3 sequence for each 
investigated derivative with most pronounced 
changes occurring if both residues are 
phosphorylated. This correlation and synergism 
most likely arise from the spatial proximity of 
TyrN and TyrC as they are located close to each 
other within the ligand binding groove forming the 
same “functional unit” (Pocket I) of the domain. 
 
SH3 domain tyrosine-phosphorylation does not 
regulate the dimerization of ABL kinases 
ABL1 have been shown to oligomerize at 
high levels of expression in COS cells (15). 
Moreover, dimerization of the full length ABL 
kinases might promote their activation (16-18). As 
an introduced phosphate group may promote (or 
interfere with) the formation of dimers/oligomers, 
and several SH3 domains have already been 
shown to form homodimers by different 
mechanisms (19-22), we assessed the effect of 
phosphorylation on the oligomeric state of ABL1 
SH3 and ABL2 SH3. We found that pTyrN was 
indeed involved in crystal contacts in both the 
crystal structures of ABL1 SH3pYn/pYc and 
ABL2 SH3pYn/pYc (Fig. S6). This residue forms a 
salt bridge with a Lys residue (Lys103 in ABL1, 
Lys130 in ABL2) of a symmetry-related 
molecule, indicating a possible monomer-dimer 
equilibrium that may exist in solution and might 
be regulated by phosphorylation of TyrN. 
Moreover, all four crystal structures (ABL1 SH3, 
ABL2 SH3, ABL1 SH3pYn/pYc, ABL2 SH3pYn/pYc, 
PDB: 4jjc, 5np3, 5np2, 5np5, respectively) shared 
a very similar hydrophobic crystal contact surface 
built by the same cluster of residues that seemed 
ideal for forming homodimers (Fig. S6). 
However, both small angle X-ray 
scattering (SAXS) and dynamic light scattering 
(DLS) analysis showed that the radius of gyration 
(Rg) of ABL1 SH3 increased by only ~0.1 nm 
upon phosphorylation. This is consistent with the 
incorporation of the phosphate groups, but not 
with dimerization (Fig. S7, Table S5). Direct 
comparison of our crystal structure with the SAXS 
profile assuming a monomer-dimer equilibrium 
model indicated ~10% and ~20% dimeric fraction 
for ABL1 SH3 and ABL1 SH3pYn/pYc, 
respectively (chi2~0.8). The fact that neither the 
protein concentration (data not shown), nor 
phosphorylation shifted the monomer-to-dimer 
ratio effectively in these experiments suggests that 
dimerization of this SH3 domain is not regulated 
by tyrosine-phosphorylation and the observed 
dimeric fraction was most likely the result of 
non-specific protein aggregation. 
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To complement these studies, 
oligomerization was further investigated by NMR 
relaxation experiments (Figure S8, Table S6). 
Phosphorylation resulted in a slight perturbation of 
atomic relaxation rates of ABL1 SH3 with no 
measurable effect on macroscopic dynamic 
properties. Singly-phosphorylated variants 
(ABL1 SH3YnF/pYc and ABL1 SH3pYn/YcF) showed 
a similar behavior. The highly similar relaxation 
properties are manifested in nearly identical values 
of rotational correlation times (τc) for the four 
ABL1 SH3 variants (Table S6) corresponding to 
the expected value for a ~7 kDa globular protein in 
aqueous buffer. Based on τc, Rg was calculated for 
all SH3 variants. A good correlation between the 
DLS/SAXS- and NMR-derived parameters was 
found, although, DLS and SAXS slightly 
overestimated Rg. This is most likely explained by 
the fact that while the DLS and SAXS derived 
parameters are affected by the presence of 
oligomers, the NMR-derived parameters reflect 
solely the properties of the monomeric fraction. 
The oligomeric fraction might be heterogenous 
and thus not be detectable in NMR. 
We conclude that neither the 
phosphorylation of pTyrN nor the phosphorylation 
of pTyrC changes the monomeric state of 
ABL1 SH3 (or ABL2 SH3, data not shown) in 
solution. 
 
Discussion 
Identification of major regulatory tyrosine 
phosphorylation sites in SH3 domains 
In this work, we performed a database 
analysis for tyrosine phosphorylation in SH3 
domains. A previous study identified TyrN within 
the conserved “ALpYDY” motif as the most 
preferred phosphorylation site (4). Here we found 
that TyrC within the “YFPSNpYV” motif (Fig. 2) 
is another prominent site, with even more 
occurrences in the human phosphoproteome 
(Table 2 and Table S2). Our experimental strategy 
allowed us to obtain phosphorylated SH3 domains 
in large quantities that meet the requirements of in 
vitro biochemical and even structural studies. We 
observed that phosphorylation of either TyrN or 
TyrC in the SH3 domain of ABL1 or ABL2 
interferes with partner binding. Simultaneous 
phosphorylation of both residues, which is 
catalyzed by several Src-family kinases in vivo, 
has a similar effect (8). In other human SH3 
domains, phosphorylation not only occurs most 
frequently on these tyrosine residues, but in many 
cases, both modifications were observed in the 
same protein (See Table 2 and Table S2). All these 
findings strongly suggest that tyrosine kinases may 
generally accept both TyrN and TyrC as substrates 
and phosphorylation of one of these residues does 
not interfere with the phosphorylation of the other. 
 
Effects of TyrC phosphorylation 
Phosphorylation of TyrC resulted in total 
inhibition of ligand binding in our experiments. As 
TyrC lies between two hydrophobic binding 
pockets in the middle of the binding groove, the 
introduced phosphate group fully occupies the 
space that would be necessary for ligands with 
polyproline-type II helix conformation. In 
agreement with this, all TyrC-type 
phosphorylation events are known to inhibit 
partner binding in other proteins. For example, the 
EGF-induced phosphorylation of cortactin SH3 
disrupts the interaction with TIP150 (23). 
Phosphorylation of TyrC in the C-terminal SH3 
domain of GRB2 by BCR-ABL or EGFR, results 
in the inhibition of Sos binding (24). This 
mechanism represents a negative regulatory loop 
limiting EGF-mediated signaling in time (24) and 
also  allows other signaling pathways to 
antagonize EGF-induced MAP kinase activation 
and cell proliferation (25,26). Phosphorylation of 
TyrC in VAV1 SH3 interferes with autoinhibitory 
intramolecular interactions leading to the 
activation of the protein (27). 
 
Effects of TyrN phosphorylation 
Phosphorylation of TyrN was found to 
inhibit ligand binding significantly in this work 
(see Fig. 3/B and 3/C). Interestingly, while this 
modification in Endophilin A2 is known to disrupt 
the interaction with dynamin (28,29), it does not 
inhibit the interaction with FAK (28). Moreover, 
TyrN-type phosphorylation of the adaptor protein 
ABI1 seems to enhance the interaction with ABL1 
(30). Phosphorylation of TyrN in the Tec family 
tyrosine-kinase BTK was found to inhibit binding 
to WASP while not influencing the interaction 
with c-Cbl and was even required for the 
interaction with kinase-active SYK (31). These 
observations indicate that TyrN (and maybe TyrC) 
phosphorylation can be part of more complex 
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molecular level mechanisms in vivo. For example, 
other regulated domain-level interactions may 
exist in parallel in multidomain proteins and their 
complexes that depend on the inhibition of SH3 
domain function. TyrN phosphorylation might also 
be involved in the activation of autoregulated 
multidomain-proteins by disrupting autoinhibitory 
intramolecular interactions.  One example is the 
Tec-family tyrosine-kinase ITK, where TyrN 
phosphorylation extends the duration of kinase 
activation (32,33). This modification and also the 
phosphorylation of the homologous site in BTK 
may serve as “checkpoints” altering the interaction 
profile of these kinases with other proteins, 
thereby controlling the transition between early 
and late activation events (32,34,35). 
 
Regulation of ABL kinases by SH3 domain 
tyrosine phosphorylation 
Here, we presented the crystal structures 
of two closely related tyrosine-phosphorylated 
SH3 domains: ABL1 SH3pYn/pYc and 
ABL2 SH3pYn/pYc. Only minor changes were 
observed in the structures upon phosphorylation; 
however, the ability of the SH3 domains to bind 
peptide ligands was compromised by the 
phosphate groups, mainly by steric blocking of the 
binding groove. Activity of the kinase domain in 
ABL1 and ABL2 are regulated by autoinhibition 
(36,37). In the “closed”, inactive conformation, the 
SH3 domain binds to the proline-rich linker 
between the SH2 and kinase domains (36,37). 
Tyrosine phosphorylation within the ligand 
binding groove of the SH3 domain disrupts this 
interaction in vivo (7,8). Although we could not 
observe any interaction between the recombinant 
ABL1 and ABL2 SH3 domains and a synthetic 
peptide corresponding to this linker in our 
experiments (data not shown), our results 
demonstrate that either the phosphorylation of 
TyrN or TyrC strongly interferes with ligand 
binding. Phosphorylation of any of these residues 
or both may likely lead to the activation of ABL 
kinases and inhibit their SH3-mediated 
interactions with external ligands. Interestingly, 
while the non-receptor tyrosine kinase SRC is 
regulated by a similar autoinhibitory mechanism, 
phosphorylation of TyrC only inhibits partner 
binding but not required for the activation of the 
kinase (38). 
Although our crystal structures raised the 
possibility of a monomer–dimer equilibrium 
regulated by the phosphorylation of TyrN, we 
demonstrated by DLS, SAXS, and NMR that 
neither the phosphorylation of TyrN nor the 
phosphorylation of TyrC affects the monomeric 
state of these domains in solution. 
No phosphorylation of Tyr112 in ABL1 or Tyr139 
in ABL2 was observed in this study. These 
residues are not part of the ligand binding groove 
and they do not contribute to any intramolecular 
interaction necessary for the formation of the 
autoinhibited conformation of ABL kinases (37). 
Therefore, it seems to be unlikely that there is any 
effect associated with their phosphorylation on the 
known functions of ABL1 SH3 or ABL2 SH3, 
including the binding of external ligands. To the 
best of our knowledge, there has been no 
information reported on the regulatory functions of 
these phosphorylation events so far. 
 
Summary 
 In this work, we recognized novel major 
tyrosine phosphorylation sites in the binding 
groove of SH3 domains and demonstrated that 
SH3 domain tyrosine phosphorylation strongly 
inhibits the interaction with proline-rich ligands 
due to the steric blocking of the ligand binding 
groove by the phosphate groups. Phosphorylation 
is not followed by significant structural 
rearrangements or oligomerization of the domains. 
Based on the occurrence of phosphotyrosine 
residues in homologous positions of many human 
SH3 domains, this seems to be a widespread 
mechanism regulating a significant part of the 
SH3-interactome in cells. 
 
Note. While this manuscript was being prepared 
for publication, an article by Dionne et al. (39) 
appeared reporting the phosphorylation of TyrC 
residues in the SH3 domains of NCK by the 
receptor tyrosine kinase Eph4a. Their findings 
confirm our conclusions showing that 
phosphorylation of TyrC inhibits ligand binding 
and functions as a negative regulatory loop 
through which receptor tyrosine kinases terminate 
signaling. 
 
Experimental procedures 
Sequence analysis of SH3 domains and 
identification of phosphorylation sites 
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Sequences of human SH3 domains were 
obtained from UniProt (40) and subsequently 
aligned by Clustal Omega (41). The alignment was 
reviewed and the boundaries of SH3 domains were 
corrected manually. Tyrosine phosphorylation 
sites were mapped based on both high- and 
low-throughput data from PhosphoSitePlus (42). 
All non-phosphorylated SH3 domain sequences 
were removed and the resulting multiple alignment 
was used as a template to generate a sequence logo 
by using WebLogo (43). 
 
DNA constructs 
The TEV protease gene cloned into a 
bacterial expression vector was a kind gift of Dr. 
László Nyitray. DNA constructs harboring the 
coding region of human ABL1, ABL2 and 
EphB1 kinases were obtained from Addgene. 
Sequences corresponding to the SH3 domain of 
ABL1 (Uniprot accession number: P00519, 
residues: 64-120) and ABL2 (Uniprot accession 
number: P42684, residues: 110-166) and the 
kinase domain of EphB1 receptor (Uniprot 
accession number: P54762, residues: 612-892) 
were amplified by PCR and subcloned into a 
modified pET vector encoding a His-tag followed 
by TEV protease recognition site by using NdeI 
and BamHI restriction enzymes. Mutants of the 
ABL1 and ABL2 SH3 domains were generated 
by PCR by using a third oligonucleotide carrying 
the base changes necessary for the mutations. All 
constructs were verified by DNA sequencing 
(Eurofins Genomics). 
 
Protein expression and purification 
Wild-type and mutant SH3 domains of 
ABL kinases and the kinase domain of EphB1 
receptor were expressed in E. coli Rosetta pLysS 
(Novagen) and Arctic Express (Agilent 
Technologies) cells, respectively. Cells were 
grown in 2YT medium up to OD600 = 0.7 at 37 °C 
and induced overnight with 0.5 mM IPTG at 
16 °C. The 15N–enriched SH3 domains were 
expressed in E. coli Rosetta pLysS cells. Cultures 
were grown in 4 × 1000 ml 2YT medium up to 
OD600 = 0.7 at 37 °C. Cells were harvested by 
centrifugation and resuspended in 1 l Minimal 
Medium containing 1 g/l 15N–NH4Cl and induced 
by 0.5 mM IPTG at 37 °C for 4 h. Purification of 
all proteins followed the same protocol. After 
centrifugation, cells were resuspended in lysis 
buffer (50 mM Na2HPO4, 500 mM NaCl, 0.25 mM 
TCEP, pH = 8.0) and subsequently lysed by 
lysozyme treatment, one freeze-thaw cycle, and 
sonication. Proteins were purified by immobilized 
metal affinity chromatography by using 
Profinity™ IMAC Ni-charged Resin (BioRad). 
Fractions containing the protein of interest were 
pooled and subsequently dialyzed against lysis 
buffer. His-tags were cleaved by TEV protease 
digestion. To remove the protease, residual 
undigested protein molecules and digested 
His-tags, samples were loaded again onto a 
Ni-charged IMAC column. The flow-through was 
collected, dialyzed against buffer “A” (20 mM 
TRIS, pH = 8.0) and further purified by anion 
exchange chromatography (HiTrapQ column) 
applying a linear gradient of buffer “B” (20 mM 
TRIS, 1M NaCl, pH = 8.0). Finally, protein 
samples were dialyzed against TRIS Buffered 
Saline (TBS) supplemented with TCEP (20 mM 
TRIS, 150 mM NaCl, 0.5 mM TCEP, pH = 7.6), 
concentrated by ultrafiltration, aliquoted and 
stored at -80 °C. 
 
SH3 domain phosphorylation 
In vitro kinase reactions were performed 
by the recombinant kinase domain of EphB1 
receptor in a buffer containing (20 mM TRIS, 150 
mM NaCl, 2 mM ATP, 10 mM MgCl2, 0.5 mM 
TCEP, 0.01% Triton-X 100, pH = 7.6) at 30 °C 
overnight. Typical concentrations of substrates and 
the kinase was 500 µM and 10 µM in reaction 
mixtures, respectively. Reactions were stopped by 
the addition of 0.5 M EDTA pH = 7.6 (20 µM 
final concentration). Samples were diluted with 
Buffer “A” to reach a final NaCl concentration of 
15 mM. Phosphorylated SH3 domains were 
separated by High Performance Liquid 
Chromatography (HPLC) by using a Sepax 
Proteomix SAX-NP3 (strong anion exchanger) 
column and a linear gradient of Buffer “A” and 
Buffer “B”. Fractions were analyzed by mass 
spectrometry to identify the number of modified 
tyrosines and their positions within the sequence. 
(See details in Supporting Information.) 
 
Peptide synthesis 
The synthetic peptides corresponding to 
the SH3 binding motif of 3BP-2 
(HPPAYPPPPVPT, Uniprot accession number: 
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P78314, residues: 200-211) and ABI2 
(TPPTQKPPSPPMS, Uniprot accession number: 
Q9NYB9, residues: 175-187) were obtained from 
GeneScript. The N- and C-termini of the peptides 
were acetylated and amidated, respectively. 
 
Ligand binding assays (fluorescence 
spectroscopy) 
Titrations of the ABL1 and ABL2 SH3 
domains by peptide ligands corresponding to the 
ABL1 SH3-binding linear motif of 3BP-2 and 
ABI2 (HPPAYPPPPVPT and TPPTQKPPSPPMS, 
respectively) were followed by the intrinsic 
tryptophan fluorescence signal. Prior to titrations, 
SH3 samples were dialyzed against Phosphate 
Buffered Saline (PBS) supplemented with 0.5 mM 
TCEP and the peptide ligands were also dissolved 
in the same buffer. Titrations were performed by 
pipetting the titrant solution (3BP-2 or ABI2 
peptide, 500 µM and 1.7 mM, respectively) in 2 µl 
steps into the cuvette. The starting volume and 
concentration of the SH3 solutions in the cuvette 
was 800 µl and 5 µM, respectively. Experiments 
were carried out at 25 °C by using a FluoroMax-3 
spectrofluorometer (HORIBA Scientific). 
Excitation of the fluorophores was performed at 
295 nm with a spectral bandwidth of 2 nm. 
Emission scans were acquired in the wavelength 
range from 310 nm to 400 nm with an emission 
bandwidth of 2 nm. Titrations were followed at 
318 nm (the difference between the fluorescence 
intensities of the apo- and ligand-bound states was 
the highest at this wavelength). The average signal 
intensity and standard deviation of three 
independent titrations was plotted against the 
volume of the titrant. Data were fitted by the 
following equation to determine the dissociation 
constants: 
I = a[A]t
′ + (b − a)
Kd+[A]t
′ +[B]t
′ −√(Kd+[A]t
′ +[B]t
′ )2−4[A]t
′ [B]t
′
2
  
Where:  
[A]t
′ =
CAVA
VA +  VB
 
is the total concentration of the SH3 domain in the 
cuvette at each point of titration, 
[B]t
′ =
CBVB
VA +  VB
 
is the total concentration of the ligand peptide in 
the cuvette at each point of titration, Kd is the 
dissociation constant, CA and CB are the 
concentrations of the stock solutions, VA and VB 
are the total volumes of the stock solutions mixed 
at the given point of titration, a and b are the 
theoretical fluorescence intensities of the 
ABL1 SH3 solution and the ABL1 SH3 - ligand 
peptide complex solution at one molar 
concentration, respectively. 
 
CD spectroscopy 
Circular Dichroism (CD) spectra were 
recorded at 25 °C in the wavelength range from 
190 nm to 250 nm (1 nm increments) on a 
JASCO J-715 Circular Dichroism 
Spectropolarimeter (JASCO Inc.). The scanning 
speed was set to 20 nm/min and the spectral 
bandwidth was 2 nm. Protein samples were 
dialyzed against CD buffer (50 mM phosphate, 
pH = 7.4) overnight and diluted to a concentration 
of 20 µM prior to the experiments. The spectrum 
of the buffer was subtracted from each protein 
spectrum. Corrected far-UV CD spectra were 
analyzed by the BeStSel (http://bestsel.elte.hu/) 
secondary structure prediction server (44). 
 
Protein crystallization 
All proteins (ABL2 SH3, 
ABL2 SH3pY116/pY161, ABL1 SH3pY89/pY134) were 
dialyzed twice against TBS supplemented with 
TCEP and sodium-azide (20 mM TRIS-HCl, 
150 mM NaCl, 3 mM NaN3, 0.5 mM TCEP, pH = 
7.6) and concentrated to ~750 µM using Amicon 
Ultra-15 3K Centrifugal Filter Devices 
(Millipore). Crystals were grown using the 
hanging drop vapor diffusion method at 293 K 
with a reservoir solution of 0.8 M sodium citrate, 
0.1 M sodium cacodylate, pH = 6.5 in the case of 
ABL1 SH3pY89/pY134, 1.8 M di-sodium DL-malate, 
pH = 7.0 in the case of ABL2 SH3 and 1.8 M 
(NH4)2SO4, 0.1 M sodium acetate, pH = 4.6 in the 
case of ABL2 SH3pY116/pY161. Drops were 
composed of 1 µl reservoir solution and 1 µl 
protein solution. Crystals were soaked in reservoir 
solution supplemented with 15% glycerol for ~30 
seconds and subsequently cooled in liquid 
nitrogen. 
X-ray diffraction experiments were 
performed at beamline P13 of the PETRA III 
synchrotron source (EMBL Hamburg). Data were 
integrated with XDS (45) and the phase problem 
was solved by PHASER (46). A high-resolution 
X-ray structure of ABL1 SH3 was used as 
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searching model (PDB: 4JJC). The MR search 
identified 4, 2 and 2 molecules in the asymmetric 
unit of structure ABL2 SH3, ABL2 SH3pY116/pY161 
and ABL1 SH3pY89/pY134, respectively. Structure 
refinement was carried out in Phenix (47) and 
modeling was done in Coot (48). The structures 
were deposited in PDB under reference codes 
5np3, 5np5 and 5np2. Crystallographic data and 
refinement statistics are shown in Table S3. 
 
Small Angle X-ray Scattering (SAXS) 
experiments 
SAXS experiments were carried out at the 
BM29 beamline at ESRF, Grenoble. Prior to the 
measurements, samples were dialyzed against TBS 
supplemented with 0.5 mM TCEP. A dilution 
series was measured from 2.8 mg/ml to 0.4 mg/ml 
to reduce the inter-particle effect from the 
scattering profile but no concentration dependent 
changes were observed during data collection. 
Data were analyzed using the ATSAS program 
package (49). Primary data was analyzed with 
PRIMUS (50). Fitting to the monomeric crystal 
structure was performed with CRYSOL (51) and 
to fit with the monomer-dimer ensemble we used 
OLIGOMER (50). The structure of the dimer was 
assumed to be identical to the crystallographic 
dimer stabilized by the interactions of pTyr89 in 
ABL1 SH3 (Fig. S6). 
 
Dynamic Light Scattering 
The hydrodynamic size distribution profile 
was determined by an Avid Nano W130i 
instrument at 25 °C. Prior to the measurements, 
samples were dialyzed against TBS supplemented 
with 0.5 mM TCEP. Protein concentration of 
ABL1 SH3 and ABL1 SH3pTyr89/134 was 5.05 
mg/ml and 3.82 mg/ml, respectively. Rg values 
were calculated from the experimental Rh using 
the scaling factor 0.775. 
 
NMR spectroscopy 
Phosphorylation induced structural 
changes were monitored by two-dimensional 
1H-15N HSQC NMR measurements (52) 
performed on uniformly [U-15N]-enriched wild 
type and mutated (Tyr89Phe and Tyr134Phe) 
ABL1 SH3. Experiments were carried out on a 
600 MHz Varian NMR System spectrometer 
equipped with a 5 mm indirect detection triple 
resonance (1H13C15N) z-axis gradient probe in PBS 
buffer pH 7.2 containing 3mM NaN3 and 0.5 mM 
TCEP at 25 °C. 
Resonance assignment was obtained on 
uniformly [U-15N]-enriched ABL1 SH3 at 25 °C 
using a combination of two-dimensional (2D) 
1H-15N HSQC (52), three-dimensional (3D) 
1H-15N TOCSY-HSQC (τm = 120 ms) and 
1H-15N NOESY-HSQC (τm = 250 ms) (53), 
2D 1H-1H TOCSY (τm = 120 ms) (54), 
1H-1H NOESY (τm = 50, 100, 250 ms) (55), and 
natural abundance 1H-13C HSQC (56) experiments. 
Spectral processing, computer-assisted spin-
system analysis, and resonance assignment were 
carried out using Felix 2004 (Accelrys, Inc.), To 
obtain the 1H, 15N assignment of phosphorylated 
derivatives, the assignment of non-phosphorylated 
ABL1 SH3 was transferred. Combined (1HN, 15N) 
chemical shift perturbations were calculated using 
the equation of Δδ1HN,15N = √[(Δδ2HN+Δδ2N/25)/2] 
(57). 
The 15N relaxation measurements 
(52,58,59) were collected on non-phosphorylated 
and phosphorylated derivatives (pY89, pY134, 
pY89pY134) of [U-15N]-enriched ABL1 SH3 at 
25 °C at a magnetic field strength of 14.1 T 
(corresponding to 15N Larmor frequency of 
60 MHz). Backbone amide 15N R1 values were 
measured from a series of eight spectra with the 
following relaxation delay times: 50, 100, 170, 
240, 340, 480, 630, 800 ms and 50, 100, 170, 240, 
420, 610, 720, 800 ms. Amide 15N R2 values were 
obtained similarly: 10, 30, 50, 70, 110, 170, 210, 
250 ms and 10, 30, 50, 90, 130, 150, 170, 230 ms. 
Fourier-transformation of free induction decays 
was performed using Felix 2004 (Accelrys, Inc.). 
For relaxation analysis, the transformed and 
phased spectra were imported into CCPNMR. 
Rotational correlation times (τc) were calculated 
from 15N R1, R2 relaxation rates using the 
corresponding equation in Kay et al. (60) 
considering the J(0) and J(ωN) spectral density 
terms. Hydrodynamic radii (Rh) were derived 
based on the equation of τc = 4πηH2ORh3/3kBT, 
where ηH2O is the viscosity of water, T is the 
temperature and kB is the Boltzmann constant. 
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Table 1. Dissociation constants determined by intrinsic tryptophan fluorescence-based titrations using 
3BP-2-derived (HPPAYPPPPVPT) and ABI2-derived (TPPTQKPPSPPMS) ligand peptides. Errors 
represent the standard error of fitting. 
 
Dissociation constant (μM) 
3BP-2-derived ligand  ABI2-derived ligand 
ABL1 SH3 1.7±0.2   ABL1 SH3 93±2 
ABL1 SH3pYn/pYc -  ABL1 SH3pYn/pYc - 
ABL1 SH3YcF 3.5±0.3  ABL1 SH3YcF 116±16 
ABL1 SH3pYn/YcF >100  ABL1 SH3pYn/YcF Very weak interaction 
ABL1 SH3YnF 4.4±0.7  ABL1 SH3YnF 126±16 
ABL1 SH3YnF/pYc -   ABL1 SH3YnF/pYc - 
ABL2 SH3 2.2±0.2  ABL2 SH3 158±22 
ABL2 SH3pYn/pYc -  ABL2 SH3pYn/pYc - 
ABL2 SH3YcF 11±2  ABL2 SH3YcF 186±17 
ABL2 SH3pYn/YcF >100  ABL2 SH3pYn/YcF Very weak interaction 
ABL2 SH3YnF 6.0±0.1  ABL2 SH3YnF 182±29 
ABL2 SH3YnF/pYc -  ABL2 SH3YnF/pYc - 
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Table 2. “N”- and “C”-type tyrosine phosphorylation in SH3 domains. ABI1: ABL interactor 1, ABI2: 
ABL interactor 2, ABL1: Abelson tyrosine-protein kinase 1, ABL2: Abelson tyrosine-protein kinase 2, 
ARHGAP12: Rho GTPase-activating protein 12, ARHGAP42: Rho GTPase-activating protein 42, 
BAIAP2L1: Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1, BCAR1: Breast 
cancer anti-estrogen resistance protein 1, BTK: Tyrosine-protein kinase BTK, CRKL: Crk-like protein, 
CTTN: Src substrate cortactin, DNMBP: Dynamin-binding protein, EPS8: Epidermal growth factor 
receptor kinase substrate 8, EPS8L2: Epidermal growth factor receptor kinase substrate 8-like protein 2, 
EPS8L3: Epidermal growth factor receptor kinase substrate 8-like protein 3, FGR: Tyrosine-protein 
kinase Fgr, FRK: Tyrosine-protein kinase FRK, FYN: Tyrosine-protein kinase Fyn, GRAP2: GRB2-
related adapter protein 2, GRB2: Growth factor receptor-bound protein 2, ITK: Tyrosine-protein kinase 
ITK, ITSN1: Intersectin-1, ITSN2: Intersectin-2, LASP1: LIM and SH3 domain protein 1, LYN: 
Tyrosine-protein kinase Lyn, MAP3K21: Mitogen-activated protein kinase kinase kinase 21, MAP3K9: 
Mitogen-activated protein kinase kinase kinase 9, NEDD9: Neural precursor cell expressed 
developmentally down-regulated protein 9, NOSTRIN: Nitric oxide synthase traffic inducer, PACSIN3: 
Protein kinase C and casein kinase substrate in neurons protein 3, PIK3R1: Phosphatidylinositol 3-kinase 
regulatory subunit alpha, PLCG2: Phospholipase C-gamma-2, SASH1: SAM and SH3 domain-containing 
protein 1, SASH3: SAM and SH3 domain-containing protein 3, SH3GL1: Endophilin-A2, SH3PXD2A: 
SH3 and PX domain-containing protein 2A, SH3PXD2B: SH3 and PX domain-containing protein 2B, 
SH3RF1: E3 ubiquitin-protein ligase SH3RF1 /SH3 domain-containing RING finger protein 1, SH3RF3: 
SH3 domain-containing RING finger protein 3, SORBS2: Sorbin and SH3 domain-containing protein 2, 
SPTA1: Spectrin alpha chain, erythrocytic 1, SPTAN1: Spectrin alpha chain, non-erythrocytic 1, SRC: 
Proto-oncogene tyrosine-protein kinase Src, TEC: Tyrosine-protein kinase Tec, TXK: Tyrosine-protein 
kinase TXK, VAV1: Proto-oncogene vav, VAV3: Guanine nucleotide exchange factor VAV3, YES1: 
Tyrosine-protein kinase Yes, GEF: Guanine nucleotide exchange factor, HTP: high-throughput, LTP: 
low-throughput  
 
Protein 
Uniprot 
Identifier 
Function 
SH3 Domain 
Position 
pTyr 
Position 
Number of 
HTP Studies 
pTyr 
Type 
pTyrN only 
ABI2 Q9NYB9 Adaptor/Scaffold  451-510 460 5 N 
BCAR1 P56945 Docking (Cas scaffolding protein family)  3-65 12 3 N 
BTK Q06187 Tyr kinase (Tec family)  214-274 223 261 N 
CRKL P46109 Adaptor/Scaffold  123-183 132 127 N 
EPS8 Q12929 Adaptor/Scaffold  531-590 540 28 N 
EPS8L2 Q9H6S3 Adaptor/Scaffold  492-551 501 4 N 
EPS8L3 Q8TE67 Adaptor/Scaffold  450-509 459 3 N 
FGR P09769 Tyr kinase (Src family)  77-138 86 10 N 
FYN P06241 Tyr kinase (Src family)  82-143 91 11 N 
ITSN1 Q15811 Adaptor/Scaffold  913-971 922 1 N 
NEDD9 Q14511 Docking (Cas scaffolding protein family)  3-65 12 4 N 
NOSTRIN Q8IVI9 Adaptor/Scaffold  438-497 447 1 N 
PLCG2 P16885 Phospholipase  769-829 778 6 N 
SH3GL1 Q99961 Membrane binding  306-365 315 5 N 
SH3PXD2B A1X283 Adaptor/Scaffold  221-280 230 2 N 
SH3RF1 Q7Z6J0 Adaptor/Scaffold  134-193 143 1 N 
       445-506 454 1 N 
SH3RF3 Q8TEJ3 Adaptor/Scaffold  464-525 473 1 N 
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SPTA1 P02549 Cytoskeleton  977-1036 986 28 N 
TXK P42681 Tyr kinase (Tec family)  82-142 91 2 N 
pTyrC only 
ARHGAP12 Q8IWW6 GTPase activator  12-74 68 1 C 
ARHGAP42 A6NI28 GTPase activator  816-874 870 1 C 
BAIAP2L1 Q9UHR4 Adaptor/Scaffold  339-402 396 1 C 
CTTN Q14247 Adaptor/Scaffold  492-550 545 22 C 
DNMBP Q6XZF7 Adaptor/Scaffold  1513-1576 1570 1 C 
FRK P42685 Tyr kinase (Src family)  42-110 104 27 C 
GRAP2 O75791 Adaptor/Scaffold  271-330 324 7 C 
GRB2 P62993 Adaptor/Scaffold  156-215 209 208 C 
ITSN1 Q15811 Adaptor/Scaffold, GEF  1074-1138 1132 8 C 
       1155-1214 1208 1 C 
ITSN2 Q9NZM3 Adaptor/Scaffold, GEF  898-956 950 1 C 
LASP1 Q14847 Adaptor/Scaffold  202-261 257 4 C 
LYN P07948 Tyr kinase (Src family)  63-123 117 3 C 
MAP3K21 Q5TCX8 Ser/Thr kinase (MAP3K subfamily)  38-102 96 3 C 
MAP3K9 P80192 Ser/Thr kinase (MAP3K subfamily)  52-116 110 1 C 
PIK3R1 P27986 Adaptor/Scaffold  3-79 73 1 C 
SASH1 O94885 Adaptor/Scaffold  557-614 609 1 C 
SASH3 O75995 Adaptor/Scaffold  176-232 228 3 C 
SH3PXD2A Q5TCZ1 Adaptor/Scaffold  266-325 319 1 C 
SORBS2 O94875 Adaptor/Scaffold  938-999 993 1 C 
       863-922 916 3 C 
       1041-1100 1096 1 C 
pTyrN and pTyrC 
ABI1 Q8IZP0 Adaptor/Scaffold  446-505 455 8 N 
        499 1 C 
ABL1 P00519 Tyr kinase (ABL family)  61-121 70 12 N 
        115 220 C 
ABL2 P42684 Tyr kinase (ABL family)  107-167 116 10 N 
        161 219 C 
GRB2 P62993 Adaptor/Scaffold  1-58 7 2 N 
        52 1 C 
ITK Q08881 Tyr kinase (Tec family)  171-231 180 78 N 
        225 2 C 
PACSIN3 Q9UKS6 Adaptor/Scaffold  363-424 372 3 N 
        418 7 C 
SPTAN1 Q13813 Adaptor/Scaffold  967-1026 976 3 N 
        1020 13 C 
SRC P12931 Tyr kinase (Src family)  84-145 93 2 N 
        139 LTP only C 
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TEC P42680 Tyr kinase (Tec family)  179-239 188 1 N 
        233 3 C 
VAV1 P15498 Adaptor/Scaffold, GEF  782-842 791 50 N 
        836 LTP only C 
VAV3 Q9UKW4 Adaptor/Scaffold, GEF  788-847 797 49 N 
        842 1 C 
YES1 P07947 Tyr kinase (Src family)  91-152 100 11 N 
        146 4 C 
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Figure 1. (A) Structure and ligand binding groove of SH3 domains. The SH3 domain of the tyrosine 
kinase Src in complex with a bound ligand peptide is shown as an example (PDB:1QWE). The ligand 
binding interface can be divided into three pockets that are mainly flanked by aromatic residues (blue and 
orange) and a conserved proline (yellow). Binding groove tyrosines starting from the N-terminus are 
labeled as “N”, “M1”, “M2”, and “C”. These positions are referred similarly throughout this work. One or 
more negatively charged residue of the RT-loop (Asp in Src) orient the ligand (red) by interacting with a 
positively charged residue on either side of the “PxxP” motif (Arg in this example). (B) 
Secondary-structural elements and sequence alignment of ABL1 SH3 and ABL2 SH3. Tyrosine 
phosphorylation sites (based on PhosphoSitePlus) are highlighted in red. Conserved residues of the 
binding groove are shown with backgrounds corresponding to the color-coding in panel “a”. Arrows 
indicate differences between ABL1 and ABL2. Sequence numbering is based on isoform 1B of both 
ABL1 (UniProt identifier: P00519-2) and ABL2 (UniProt identifier: P42684-1). Note that in ABL1 SH3 
and ABL2 SH3, Phe and Trp residues occupy positions "M1" and "M2", respectively. (C) Protein 
sequences of Tyr-to-Phe mutant constructs used in this work. 
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Figure 2. Sequence logo representation of the tyrosine phosphorylated human SH3 domains. Key 
conserved residues of the ligand binding groove are highlighted in gray background. The four most 
prominent tyrosine phosphorylation sites (positions 10, 12, 50 and 55, with 32, 13, 20 and 35 occurrences 
in PhosphoSitePlus, respectively) are indicated in red. (See also the full alignment in Table S2. Note that 
only positions homologous to ABL1 SH3 are shown here for simplicity.) 
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Figure 3. Tryptophan fluorescence-based titrations of ABL1 SH3 and ABL2 SH3. (A) Tryptophan 
fluorescence emission spectra of free and 3BP-2 peptide-bound ABL1 SH3 and ABL2 SH3. Ligand 
binding was associated with a remarkable blue shift. The highest intensity difference was observed at 318 
nm. (B) Complex formation between ABL1 and ABL2 SH3 variants and 3BP-2 followed by fluorescence 
intensity changes at 318 nm. Both the doubly-phosphorylated (ABL1 SH3pYn/pYc, ABL2 SH3pYn/pYc) and 
Tyr-C-phosphorylated (ABL1 SH3YnF/pYc, ABL2 SH3YnF/pYc) proteins showed total loss of ligand binding. 
The inhibitory effect of TyrN phosphorylation (ABL1 SH3pYn/YcF, ABL2 SH3pYn/YcF) was weaker but still 
substantial. (C) Complex formation between ABL1 and ABL2 SH3 variants and ABI2 followed by 
fluorescence intensity changes at 318 nm. Although the ABI2-derived ligand showed much weaker 
binding compared to 3BP-2 (dissociation constants around 100 µM), the effects of phosphorylation were 
similar. Error bars represent the standard deviation of three independent measurements. 
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Figure 4. Comparison of the non-phosphorylated and phosphorylated SH3 domains. Structural alignment 
of (A) ABL1 SH3 (light blue, PDB: 4JJC) with ABL1 SH3pYn/pYc (dark blue, PDB:5np2), (B) 
ABL2 SH3 (yellow, PDB:5np3) with ABL2 SH3pYn/pYc (orange, PDB:5np5). Key residues of the binding 
grooves are labeled and shown as sticks. 
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Figure 5. Alignment of the crystal structure of ABL1 SH3pYn/pYc and ABL1 SH3 in complex with a 
peptide ligand derived from 3BP-1 (PDB: 1ABO(14)). (A) For simplicity, only the ligand (salmon) and 
the phosphorylated domain are shown. Surfaces of the three neighboring hydrophobic pockets within the 
binding groove are shown in different colors. (B) The phosphate group of pTyrC (pTyr134) occupies the 
binding groove making it totally inaccessible for the ligand. (Both Pocket I and Pocket II are affected.). 
(C) Although the phosphate group of pTyrN (pTyr89) is located at the edge of the binding groove and this 
sidechain seems to be more flexible, steric clashes with the ligand can be expected. (Mainly Pocket I is 
affected.) 
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